Why the top of the head is affected by hair loss more than other areas, and treatments such as surgery, medications like minoxidil, finasteride, and RU58841 to treat it.
A user who shared progress pictures of their scalp using a microscope camera, demonstrating the difference between healthy and miniaturized hair. Various explanations for the cause of this were discussed, such as DHT build-up in scalp sebum causing an autoimmune response leading to inflammation and eventual hair loss, with some suggesting a do-it-yourself treatment involving adding ascorbic acid powder to shampoo.
Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.
There is no natural way to stop hair loss; pharmaceuticals like minoxidil, finasteride, and RU58841 are the only effective treatments. Some users report success with minoxidil and microneedling, while others discuss the side effects of finasteride.
Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hair growth.
Switching from oral to topical dutasteride may reduce side effects like anxiety and depression while maintaining hair health. Combining it with minoxidil, Nizoral, and dermarolling could be effective for hair preservation.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
A 24 year old male struggling with the physical and mental effects of balding, being short, and having a micropenis. Suggested treatments include taking medications such as finasteride and minoxidil, lifting weights, and trying not to compare himself to others.
Hair loss treatments, specifically, discussing the effectiveness and side effects of finasteride, minoxidil, and RU58841 in various microdoses. It also includes an updated graph which provides information on how different doses affect DHT levels, scalp skin and serum androgen levels, as well as hair count.
Treatments used to prevent and treat male pattern baldness, the difficulty in finding a permanent cure for hair loss, and the potential financial motivations of companies not wanting to find a cure.
The conversation emphasizes the importance of starting hair loss treatment early, using options like minoxidil, finasteride, RU58841, essential oils, and dermarolling, and encourages leaving the hair loss subreddit once treatment begins to avoid stress and obsession. Users shared personal success with finasteride and the motivation to start treatment to prevent future regret.
The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.
A hair transplant experience after 6 months, with 4100 grafts, which took 3 months to stop looking obvious and included finasteride treatment. It also discusses the differences between DHI and FUE methods.
The conversation discusses using NAC (N-Acetyl Cysteine) alongside minoxidil and finasteride for hair loss, with some users noting potential hairline improvement and increased energy. The original poster reduced their finasteride dosage due to mental decline and anxiety, and while NAC's effects on hair are anecdotal, it is considered low-risk with other health benefits.
A person experienced hair loss due to a crash diet and is now seeking advice on recovery, including dietary changes and potential treatments like biotin and pumpkin seed oil. They are concerned about nutrient deficiencies and considering a dermatologist visit for further guidance.
The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.
The user is concerned about starting finasteride due to potential fertility issues and is considering using minoxidil and Nizoral shampoo as alternatives for hair loss. Another user shares their experience of pausing finasteride while trying to conceive, continuing with minoxidil and Nizoral, and advises prioritizing child health over hair treatment.
Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.
Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.
Panax ginseng, specifically a ginsenoside-enriched formulation, is suggested as a potential hair growth treatment alongside finasteride and minoxidil. The user is considering trying panax ginseng despite limited availability and evidence.
A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
Existing hair loss treatments like oral finasteride, topical minoxidil, and hair transplants are still the main options, with some improvements in affordability and techniques. There is hope for enhancing these treatments, but new effective solutions are unlikely in the near future.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.